Inclusion du premier patient dans l’essai clinique de Phase 2b (ABX464-103) d’Abivax visant le traitement de la rectocolite hémorragique
Also to be discovered
Inclusion of the first patient in Abivax's Phase 2b (ABX464-103) clinical trial for the treatment of hemorrhagic rectocolitis
The main evaluation criterion is the reduction of Mayo's score to 8 weeks.
Abivax treats first rheumatoid arthritis patient in Phase 2a clinical trial
The clinical trial was approved in the following four European countries: France, Poland, Czech Republic and Hungary. ABX464 is a drug candidate in oral adent tablet form with an innovative mechanism of action and has already demonstrated positive results in hemorrhagic rectocolitis, another chronic inflammatory disease with a biological profile closely similar to rheumatoid arthritis.